Business Context and Reporting Period
This Form 6-K filing by Aurinia Pharmaceuticals Inc. is dated April 20, 2020. The registrant is a foreign private issuer reporting pursuant to Rule 13A-16 or 15D-16 under the Securities Exchange Act of 1934. The filing serves to incorporate a news release regarding a corporate governance update into the company's Registration Statement on Form F-10 (File No. 333-222413).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate announcement rather than a financial results statement.
Material Changes
The material change disclosed in this filing is the appointment of Timothy P. Walbert, an industry veteran, to the company's Board of Directors. No financial material changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, contingencies, or unusual items. The content is limited to the announcement of the new board member.
Investor Verification Checklist
- Verify the background and qualifications of the newly appointed board member, Timothy P. Walbert.
- Confirm the status of the Registration Statement on Form F-10 (File No. 333-222413) referenced in the filing.
- Review subsequent filings for the company's next scheduled financial results, as none are included here.